WinSanTor

Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

https://wefunder.com/winsantor

Total raised on Wefunder: 707002

Total investors: 324

Quick facts

  • Drug regenerating peripheral nerves (humans) - combating direct cause of peripheral neuropathy
  • Repurposed medication w/ UNPARALLELED safety profile in FINAL phase (PH3) of clinical studies (DPN)
  • UNMET need affecting 100s of millions, ignored/neglected by industry, e.g., few, if any, competitors
  • VALIDATED science rewarded by innovation grants (>$40M) and licensing deal (>$200M + royalty)
  • Strong economic MOAT (the top KOLs, patents & other intellectual property, partners and strategy)
  • CEO's past companies were snatched by tech giants Qualcomm and Apple, tech now standards in industry
  • Industry ICONS lead our board, driving disruptive and transformative changes in healthcare
  • LAST crowdfunding investment opportunity before drug approval and IPO (~2-3 years)

Team profiles

Featured investor profiles

WinSanTor

Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

Funded badge
Last Funded April 2024

$707,002

raised from 324 investors

What Investors Say

LEAD INVESTOR
Invested $150,000 this round
WinSanTor has a drug in FDA trials that shows significant promise in combating neuropathy. Neuropathy causes debilitating loss of feeling, particularly in digits that can impede simple function and even walking. It’s generally caused by diabetes, chemotherapy, or nervous system disease. This is a significant global market opportunity without similar competing compounds. The drug has been in use in western countries for 30 years which should be helpful to its approval process. In addition, WinSanTor has transitioned this compound from tablet form to topical. This reformulation may be an additional opportunity for the company for other ingestible tablets that may be converted to topical use.

What Friends Say

What People Say